题名

High-dose Quetiapine for the Treatment of Schizophrenia with Inadequate Response to Quetiapine 600 mg/day

并列篇名

以高劑量Quetiapine治療對Quetiapine劑量600毫克治療反應不佳的精神分裂症患者

DOI

10.29478/TJP.201012.0007

作者

吳坤鴻(Kuen-Hong Wu)；詹宏裕(Hung-Yu Chan)；吳俊毅(Chun-Yi Wu)；陳快樂(Happy Kuy-Lok Tan)；孫效儒(Hsiao-Ju Sun)

关键词

schizophrenia ； inadequate response ； quetiapine ； high dose

期刊名称

台灣精神醫學

卷期/出版年月

24卷4期（2010 / 12 / 01）

页次

307 - 312

内容语文

英文
英文摘要

Objectives: In this study, we aimed to determine the efficacy of high-dose quetiapine (≧800 mg/day) for Taiwanese patients with schizophrenia and with inadequate response to quetiapine 600 mg/day of more than 4 weeks. Methods: The study was a six-week, open-label study. We assessed patients' treatment response and side effects with clinical global impression-severity (CGI-S), brief psychiatric rating scale (BPRS), and extrapyramidal syndrome rating scale (ESRS). Results: Six patients participated in this study. After this six-week study, the mean dose of quetiapine was 1000 mg/day. The mean scores of BPRS and CGI-S were improved from 44.2±5.5 to 35.5±18.1 (p=0.344) and 4.7±0.8 to 3.7±1.8 (p=0.084), respectively. Four patients met the criteria of treatment responder and no patients suffered from severe adverse events. Conclusion: Although no significant statistical differences in this study were observed due to small sample size, the improvements of mean total scores of BPRS and CGI-S were 19.7% and 21.3%, respectively, and 66.7% of the patients met treatment responder criteria. For Taiwanese patients with schizophrenia and with inadequate treatment response to quetiapine 600 mg/day, we suggest that high-dose quetiapine can be effective and tolerable.
主题分类 醫藥衛生 > 社會醫學
参考文献
  1. Arvanitis, L.A.,Miller, B.G.(1997).The Seroquel Trial 13 Study Group: Multiple fixed dose of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo.Biol Psychiatry,42,233-246.
  2. Bobes, J.,Garcia-Portilla, M.P.,Saiz ,P.A.(2002).High degree of tolerability for monotherapy with high dose of quetiapine: a case report.J Clin Psychiatry,63,1048-1049.
  3. Boggs, D.L.,Kelly, D.L.,Feldman, S.(2008).Quetiapine at high doses for the treatment of refractory schizophrenia.Schizophr Res,101,347-348.
  4. Buckley, P.F.,Goldstein, J.M.,Emsley, R.A.(2004).Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia.Schizophr Res,66,143-150.
  5. Chouinard, G.,Chouinard, R.A.,Annable, L.,Jones, B.D.(1980).Extrapyramidal symptom rating scale.Can J Neurol Sci,7,3.
  6. Leysen, J.E.,Janssen, P.M.F.,Heylen, L.(1998).Receptor interactions of new antipsychotics: relation to pharmacodynamic and clinical effects.Int J Psychiatry Clin Pract,2,3-17.
  7. Overall, J.E.,Gorham, D.R.(1988).The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling.Psychopharmacol Bull,24,97-99.
  8. Pierre, J.M.,Wirshing, D.A.,Wirshing, W.C.(2005).Highdose quetiapine in treatment refractory schizophrenia.Schizophr Res,73,373-375.
  9. Rajagopal, S.(2006).The placebo effect.Psychiatr Bull,30,185-188.
  10. Remington, G.,Kapur, S.(2000).Atypical antipsychotics: are some more atypical than others?.Psychopharmacology,148,3-15.
  11. Sparshatt, A.,Jones, S.,Taylor, D.(2008).Quetiapine dose-response relationship in schizophrenia.CNS Drugs,22,49-72.
  12. William, Guy(1976).ECDEU Assessment Manual for Psychopharmacology.Rockville, Maryland, USA:National Institute of Mental Health.
print cancel